Liang Xiaolei, Wang Ruirui, Dou Wenshan, Zhao Li, Zhou Lanxia, Zhu Junfang, Wang Kairong, Yan Jiexi
The Reproductive Medicine Special Hospital of the First Hospital of Lanzhou University, Key Laboratory for Reproductive Medicine and Embryo, Lanzhou, China.
The First Clinical Medical College, Lanzhou University, Lanzhou, China.
Drug Des Devel Ther. 2018 Oct 31;12:3691-3703. doi: 10.2147/DDDT.S181188. eCollection 2018.
Due to the emergence of multidrug resistance (MDR), traditional antileukemia drugs no longer meet the treatment needs. Therefore, new antileukemia drugs with different action mechanisms are urgently needed to cope with this situation.
Arminin 1a-C is an antimicrobial peptide (AMP) developed from the ancient metazoan marine . In this study, we first explored its antileukemia activity.
Our results showed that Arminin 1a-C formed an α-helical structure and efficaciously suppressed the viability of leukemia cell lines whether or not they were multidrug resistant or sensitive, and there were no obvious differences between these cell lines. Arminin 1a-C exhibited distinct selectivity between noncancerous and cancerous cell lines. Arminin 1a-C interfered with K562/adriamycin (ADM) cell (a kind of multidrug-resistant leukemia cell line) proliferation in a very rapid manner and formed pores in its cell membrane, making it difficult to develop resistance against Arminin 1a-C.
Our data show that Arminin 1a-C possesses great potential as a therapeutic candidate for the treatment of multidrug-resistant leukemia.
由于多药耐药(MDR)的出现,传统抗白血病药物已无法满足治疗需求。因此,迫切需要具有不同作用机制的新型抗白血病药物来应对这一情况。
Arminin 1a-C是一种从古老的后生动物海洋生物中开发出的抗菌肽(AMP)。在本研究中,我们首先探究了其抗白血病活性。
我们的结果表明,Arminin 1a-C形成了α-螺旋结构,无论白血病细胞系是否具有多药耐药性或敏感性,它都能有效抑制其活力,且这些细胞系之间无明显差异。Arminin 1a-C在非癌细胞系和癌细胞系之间表现出明显的选择性。Arminin 1a-C能非常迅速地干扰K562/阿霉素(ADM)细胞(一种多药耐药白血病细胞系)的增殖,并在其细胞膜上形成孔道,使其难以对Arminin 1a-C产生耐药性。
我们的数据表明,Arminin 1a-C作为治疗多药耐药白血病的候选药物具有巨大潜力。